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Abstract
Human parvovirus B19 occurs worldwide and causes mild or
asymptomatic disease in the form of cyclic local epidemics usually
occurring in late winter and early summer. In 2012, a dramatic
increase in cases was observed in the Public hospitals system of
Marseille, with a total of 53 cases reported. Here, we describe the
characteristics of this outbreak and compare it with the local
epidemiology of B19V infections observed during the 2002–2011
period.
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Background
Parvovirus B19 (B19V), genus Erythrovirus, family Parvoviridae, is
distributed worldwide and causes ﬁfth disease, polyarthralgia,
anaemic crisis in children with underlying haematological
diseases and intrauterine infections. B19V infections are
common during childhood and in young adults [1]. Seasonal
recrudescence is observed in spring and early summer.
Diagnostic Methods
Nucleic acid puriﬁcation was performed with the EZ1 DSP
Virus Kit onto the EZ1 Advanced XL biorobot (both from
Qiagen, Hilden, Germany) from a volume of 200 lL including
10 lL of a mixture composed of bacteriophage T4 and MS2
for process monitoring as previously described [2]. Qualitative
PCR was performed with the system described by Aberham
et al. [3]. Quantitative PCR was performed with the same
protocol, using calibration range on B19V DNA-positive
samples [3]. IgM and IgG speciﬁc for B19V were tested using
commercial ELISA tests (Biotrin International, Dublin, Ireland).
B19V cases during 2002–2011
Between 2002 and 2011, we tested annually an average of 1409
patients (range 788–1630 per year) for B19V. We detected an
average of 23.2 cases (range 8–31) of acute B19V infections for
a global frequency of cases of 1.65% of tested patients with
yearly variations from 0.64% to 2.47%. Year by year data are
presented in Fig. 1(a). The sex ratio was balanced in patients
younger than 20 years. In contrast, in patients older than
20 years, females were over-represented (Fig. 1b). The major-
ity of acute B19V cases affected young adults between 21 and
40 years (Fig. 1b). During the 10 years studied, most of the
requests (52%) for B19V serology and PCR originated from
paediatric haematology, infectious diseases, gynaecology and
internal medicine. These four specialties diagnosed 64% of all
the acute B19V infections. Each year, an increased incidence of
acute B19V infections was noted between April and July with a
peak in June (Fig. 1c). Seasonality was demonstrated by
autocorrelation.
B19V cases in 2012
In 2012, we tested 1885 patients for B19V: 1735 were tested by
serological tests IgG and IgM, 443 by qualitative PCR.
Fifty-three acute B19V infections were diagnosed: 53 had a
qualitative positive PCR, 49 B19V DNA were quantiﬁed (four
were not available) and 49 presented positive IgM (four were
not available). The detailed characteristics of these 53 cases are
presented in Table 1. The mean age was 22 years (range 1–58
median: 25 years). A sex ratio of 0.36 (39 women for 14 men)
was observed. The majority (n = 35, 66%) presented clinical/
biological manifestations that were severe enough to require
hospitalization; of the 18 remaining patients, seven patients
were discharged after admission to the emergency ward, and
nine were diagnosed after being seen as outpatients in
gynaecology, paediatric haematology, infectious diseases or
internal medicine. The patients were referred to paediatric
haematology (n = 17), obstetrics (n = 10), emergency room
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(n = 7), internal medicine (n = 6), infectious diseases (n = 4),
nephrology (n = 3), paediatrics (n = 2), oncology (n = 1),
neurology (n = 1), dermatology (n = 1), and medical staff
(n = 1). A total of 37.7% of cases affected children with a
pre-existing condition such as sickle cell disease, hereditary
spherocytosis, thalassaemia and Fanconi anaemia. Among the
11 pregnant women, six presented with severe complications
and/or negative outcome (ﬁve hydrops fetalis and three
pre-eclampsia). The six amniotic ﬂuids were tested by qualita-
tive PCR assay, and two were also tested through quantitative
PCR assay (four were not available). In 2012, 20.7% and 24.5%
of B19V acute infections involved pregnant women and children
with an increased red blood cell turnover, respectively. The
number of cases increased between April and July reaching an
unprecedented high number of cases (n = 15) observed in July.
Comparison of B19V cases in 2012 versus the 2002–2011
period
The analysis of the characteristics of acute B19V infections
observed in 2012 compared with the cases diagnosed during
FIG. 1. (a) Requests for parvovirus B19-positive cases per year (Public Hospitals of Marseille, France 2002–2012). (b) Parvovirus B19 acute
infections—Age and sex repartition (Public Hospitals of Marseille, France, 2002–2012). (c) Parvovirus B19 acute infections—Seasonnality (Public
Hospitals of Marseille, France, 2002–2012).
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the 2002–2011 period indicated that the number of acute
B19V cases was signiﬁcantly higher in 2012 (binomial test,
p <0.001; Fig. 1a). In contrast, no difference could be shown in
the composition of the two populations with more than half of
acute B19V infections diagnosed in young adults (21–40 years
old; Fig. 1b). During the two periods, the higher rate of
hospitalization suggested that symptomatic and severe infec-
tions are more often seen in females than in males. Finally, the
epidemiology was identical for both periods with an increased
number of cases during spring and summer, with a peak in
June–July (Fig. 1c), as previously reported [4,5].
Conclusion
In 2012, in the Public Hospitals of Marseille, we noticed an
increased number of cases of B19V infection relative to that
observed during the ten previous years (2002–2011). We
recorded 53 acute B19V infections, which represented a 71%
incidence increase compared with the average incidence per
year reported during the 2002–2011 period. From 2002 to
2012, (i) the annual number of B19V tests was constant; (ii) the
distribution of B19V cases was similar; and (iii) the techniques
used for diagnosis of B19V infection in the laboratory were
unchanged. Therefore, the increased number of B19V infec-
tions noticed in 2012 was not biased by modiﬁed recruitment
of patients, by number of annual tests, or by technical
modiﬁcations. However, in samples with high concentration
of B19V, the immunoglobulins may be complexed to virus
particles and not be detectable in ELISA. Thereby, acute B19V
infection might be signiﬁcantly underdiagnosed. There is no
bias in our study because the same algorithm was used for the
entire study period. In 2013, the procedure was changed to
test all samples by PCR. The unexpectedly high number of
acute B19V infections in 2012 was also noticed in England and
Wales [6]. As described previously, cases can be sporadic or
can occur in clustered outbreaks. B19V infection occurs more
frequently between late winter and early summer. Where
reportable, communities have documented not only season-
ality to B19V infections, but also cycles of local epidemics with
case numbers that can peak every 4–10 years [4–7]. In
epidemic periods, particular awareness should be granted to
pregnant women who could develop complications such as
pre-eclampsia and hydrops fetalis [8–10].
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